Lord, Abbett & Co
TMDX icon

Lord, Abbett & Co’s Transmedics TMDX Stock Holding History

Lord, Abbett & Co’s Portfolio TMDX Stock Details TMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.3M Sell
213,973
-2,900
-1% -$378K 0.07% 268
2025
Q4 		$26.4M Buy
216,873
+83,459
+63% +$10.5M 0.08% 241
2025
Q3 		$15M Sell
133,414
-7,271
-5% -$851K 0.04% 324
2025
Q2 		$18.9M Buy
+140,685
New +$15.4M 0.06% 295
2024
Q4 		– Sell
-809,135
Closed -$127M – 581
2024
Q3 		$127M Buy
809,135
+275,259
+52% +$42.4M 0.4% 60
2024
Q2 		$80.4M Buy
533,876
+228,457
+75% +$27.4M 0.26% 104
2024
Q1 		$22.6M Sell
305,419
-720,145
-70% -$59.4M 0.07% 315
2023
Q4 		$80.9M Buy
1,025,564
+352,470
+52% +$21.3M 0.28% 105
2023
Q3 		$36.9M Sell
673,094
-1,196,645
-64% -$86.1M 0.14% 215
2023
Q2 		$157M Buy
1,869,739
+15,656
+0.8% +$1.2M 0.54% 34
2023
Q1 		$140M Buy
1,854,083
+666,277
+56% +$46.1M 0.51% 37
2022
Q4 		$73.3M Buy
1,187,806
+415,733
+54% +$22.1M 0.26% 104
2022
Q3 		$32.2M Buy
+772,073
New +$33.6M 0.12% 233

Other funds holding TMDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lord, Abbett & Co's TMDX Position: Q1 2026 in Review

Lord, Abbett & Co reduced its Transmedics (TMDX) stake by 1.3% in Q1 2026, selling an estimated $378K and leaving 213,973 shares worth $21.3M. The position accounts for 0.07% of the portfolio, ranked #268.

Lord, Abbett & Co first reported a position in TMDX in Q3 2022 and has held it in 13 quarters since. The position peaked at $157M in Q2 2023. 414 funds tracked by Wall St. Rank hold TMDX as of Q1 2026.

  • Lord, Abbett & Co held 213,973 shares of Transmedics worth $21.3M as of Q1 2026.
  • Lord, Abbett & Co sold 2,900 Transmedics shares in Q1 2026, an estimated $378K.
  • Transmedics made up 0.07% of Lord, Abbett & Co's portfolio in Q1 2026, its #268 holding.
  • Lord, Abbett & Co first reported a position in Transmedics in Q3 2022 and has held it in 13 quarters since.
  • Lord, Abbett & Co's Transmedics position peaked at $157M in Q2 2023.
  • 414 funds tracked by Wall St. Rank held Transmedics as of Q1 2026.

Based on Lord, Abbett & Co's 13F filing for Q1 2026, filed 14 May 2026.